基于质谱技术的肺癌代谢标志物筛选研究进展

Research Progress in Screening Metabolic Biomarkers of Lung Cancer Based on Mass Spectrometry Technology

肺癌早期诊断可显著改善患者预后,提高患者生存率。肺癌发生发展进程伴随机体代谢物变化,因此通过对体内代谢通路的全面检测,进而结合生物信息学工具分析代谢应答变化,可高效筛选肺癌相关代谢标志物,有助肺癌早期发现。近年来已开发多种代谢检测技术用于肺癌代谢标志物筛选,其中质谱技术在检测的灵敏度、特异性、分析速度、多指标平行检测等方面展现出显著优势,因此在癌症诊断、疾病监测和治疗等领域有重要地位。该文概述了质谱技术方法在肺癌临床诊疗应用中的最新研究进展,并对应用质谱方法学研究生物标志物的前景进行了系统性展望。通过对近期研究的深入了解,预期将进一步理解肺癌代谢特征,为肺癌早期诊断和治疗提供精准评估技术手段。

Early diagnosis of lung cancer can significantly improve patient prognosis and increase patient survival rate.The occurrence and development of lung cancer is accompanied by changes in metabolites in the body.Therefore,comprehensive detection of metabolic pathways in the body,combined with bioinformatics tools to analyze metabolic response changes,can efficiently screen lung cancer-related metabolic markers,which can help to detect lung cancer in its early stages.In recent years,various metabolic detection technologies have been developed for screening metabolic biomarkers in lung cancer.Among them,mass spectrometry technology has shown significant advantages in sensitivity,specificity,analysis speed,multi-index parallel detection,etc.Therefore,it plays an important role in cancer diagnosis,disease monitoring,and treatment.This article summarizes the latest research progress of mass spectrometry technology in the clinical diagnosis and treatment of lung cancer,and provides a systematic outlook on the prospects of applying mass spectrometry methodology to the discovery studies of biomarkers.Through an in-depth understanding of recent research,it is expected to further understand the metabolic characteristics of lung cancer and provide precise evaluation techniques for early diagnosis and treatment of lung cancer.